This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Celldex Nears Pivotal Decision Point for Brain Tumor Therapy

Celldex will announce the outcome of an interim analysis for a pivotal study of its brain tumor therapy Rintega within weeks.

Assume No More Biogen Drug Price Hikes? Not So Fast

The controversy over drug pricing factored into Biogen's revenue guidance for 2016.

Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy

Juno and Kite Pharma are under pressure Tuesday after U.S. government researchers published a study showing an off-the-shelf, engineered T-cell therapy could induce remissions in patients with blood cancers.

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC

Biotech news and observations to start the week.

8 Things That Could Lift Biotech Stocks Out of Bear Market

Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.

Biotech Stock Mailbag: Snow Stops Sarepta's FDA Show, so What's Next?

TheStreet's Adam Feuerstein responds to reader questions about Sarepta and its Duchenne muscular dystrophy drug eteplirsen.

Alkermes Depression Drug Failure Crimps Future Growth Outlook

Alkermes said Thursday the experimental drug ALKS 5461 failed to improve depressive symptoms in patients with hard-to-treat depression, based on negative results from two late-stage clinical trials.

Acorda Acquires Parkinson's Drug Through Biotie Buyout

Acorda's all-cash tender offer values Biotie at $363 million, or $25.60 per ADS, representing a 96% premium over the stock's closing price on Friday.

Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting

The FDA's review team appears to cast significant doubt on eteplirsen's approval chances.

Investor Apathy Keeps Biotech Stocks in the Red

Nothing at the J.P. Morgan Healthcare Conference is convincing health care investors to step up and buy biotech stocks.

Page 2 of 351
Top Rated Stocks Top Rated Funds Top Rated ETFs